Cargando…

Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis

BACKGROUND AND AIM: Recent studies evaluated the role of vamorolone in treating Duchenne muscular dystrophy (DMD), so we aimed in our Meta-analysis to assess the efficacy of vamorolone in comparison with placebo and corticosteroids for treating DMD patients. METHODS: We searched PubMed, Web of Scien...

Descripción completa

Detalles Bibliográficos
Autores principales: Elhalag, Rowan H., Motawea, Karam R., Talat, Nesreen Elsayed, Rouzan, Samah S., Shah, Jaffer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929286/
https://www.ncbi.nlm.nih.gov/pubmed/36816559
http://dx.doi.org/10.3389/fneur.2023.1107474
_version_ 1784888818128650240
author Elhalag, Rowan H.
Motawea, Karam R.
Talat, Nesreen Elsayed
Rouzan, Samah S.
Shah, Jaffer
author_facet Elhalag, Rowan H.
Motawea, Karam R.
Talat, Nesreen Elsayed
Rouzan, Samah S.
Shah, Jaffer
author_sort Elhalag, Rowan H.
collection PubMed
description BACKGROUND AND AIM: Recent studies evaluated the role of vamorolone in treating Duchenne muscular dystrophy (DMD), so we aimed in our Meta-analysis to assess the efficacy of vamorolone in comparison with placebo and corticosteroids for treating DMD patients. METHODS: We searched PubMed, Web of Science, Scopus, and Cochrane library databases. We included any randomized control trials and controlled observational studies that investigated the role of vamorolone in treating DMD patients. We used RevMan software, version 5.4. to perform our meta-analysis. RESULTS: After a search of the literature, 4 studies were included in the meta-analysis; the total number of patients included in the study is 277 patients, 125 patients in the vamorolone group, 106 in the glucocorticoids group, and 46 in placebo (steroid naïve) group. The pooled analysis showed a statistically significant association between the vamorolone group and increased TTSTAND velocity, TTRW velocity and TTCLIMB velocity compared with the placebo group (MD = 0.04, 95% CI = 0.02–0.07, p = 0.002), (MD = 0.24, 95% CI = 0.11–0.37, p = 0.0003), and (MD = 0.06, 95% CI = 0.05–0.06, p < 0.00001), respectively. Also, the analysis showed a statistically significant association between vamorolone and increased TTRW velocity and increased Height percentile for age compared with the glucocorticoid group (MD = −0.14, 95% CI = −0.26 to −0.01, p = 0.03) and (MD = 17.82, 95% CI = 3.89–31.75, p = 0.01), respectively. CONCLUSION: Our study revealed a significant association between vamorolone and increased TTSTAND velocity, TTRW velocity, and TTCLIMB velocity compared with the placebo (steroid naïve), also showed a statistically significant association between increased TTRW velocity and increased Height percentile for age compared with the glucocorticoid that enhances the privilege of vamorolone over glucocorticoid in treating DMD patients. More multicenter randomized studies are needed to support our results.
format Online
Article
Text
id pubmed-9929286
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99292862023-02-16 Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis Elhalag, Rowan H. Motawea, Karam R. Talat, Nesreen Elsayed Rouzan, Samah S. Shah, Jaffer Front Neurol Neurology BACKGROUND AND AIM: Recent studies evaluated the role of vamorolone in treating Duchenne muscular dystrophy (DMD), so we aimed in our Meta-analysis to assess the efficacy of vamorolone in comparison with placebo and corticosteroids for treating DMD patients. METHODS: We searched PubMed, Web of Science, Scopus, and Cochrane library databases. We included any randomized control trials and controlled observational studies that investigated the role of vamorolone in treating DMD patients. We used RevMan software, version 5.4. to perform our meta-analysis. RESULTS: After a search of the literature, 4 studies were included in the meta-analysis; the total number of patients included in the study is 277 patients, 125 patients in the vamorolone group, 106 in the glucocorticoids group, and 46 in placebo (steroid naïve) group. The pooled analysis showed a statistically significant association between the vamorolone group and increased TTSTAND velocity, TTRW velocity and TTCLIMB velocity compared with the placebo group (MD = 0.04, 95% CI = 0.02–0.07, p = 0.002), (MD = 0.24, 95% CI = 0.11–0.37, p = 0.0003), and (MD = 0.06, 95% CI = 0.05–0.06, p < 0.00001), respectively. Also, the analysis showed a statistically significant association between vamorolone and increased TTRW velocity and increased Height percentile for age compared with the glucocorticoid group (MD = −0.14, 95% CI = −0.26 to −0.01, p = 0.03) and (MD = 17.82, 95% CI = 3.89–31.75, p = 0.01), respectively. CONCLUSION: Our study revealed a significant association between vamorolone and increased TTSTAND velocity, TTRW velocity, and TTCLIMB velocity compared with the placebo (steroid naïve), also showed a statistically significant association between increased TTRW velocity and increased Height percentile for age compared with the glucocorticoid that enhances the privilege of vamorolone over glucocorticoid in treating DMD patients. More multicenter randomized studies are needed to support our results. Frontiers Media S.A. 2023-02-01 /pmc/articles/PMC9929286/ /pubmed/36816559 http://dx.doi.org/10.3389/fneur.2023.1107474 Text en Copyright © 2023 Elhalag, Motawea, Talat, Rouzan and Shah. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Elhalag, Rowan H.
Motawea, Karam R.
Talat, Nesreen Elsayed
Rouzan, Samah S.
Shah, Jaffer
Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis
title Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis
title_full Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis
title_fullStr Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis
title_full_unstemmed Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis
title_short Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis
title_sort efficacy of vamorolone in treatment of duchene muscle dystrophy. a meta-analysis
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929286/
https://www.ncbi.nlm.nih.gov/pubmed/36816559
http://dx.doi.org/10.3389/fneur.2023.1107474
work_keys_str_mv AT elhalagrowanh efficacyofvamoroloneintreatmentofduchenemuscledystrophyametaanalysis
AT motaweakaramr efficacyofvamoroloneintreatmentofduchenemuscledystrophyametaanalysis
AT talatnesreenelsayed efficacyofvamoroloneintreatmentofduchenemuscledystrophyametaanalysis
AT rouzansamahs efficacyofvamoroloneintreatmentofduchenemuscledystrophyametaanalysis
AT shahjaffer efficacyofvamoroloneintreatmentofduchenemuscledystrophyametaanalysis